Roche (QX) Aktie - RHHBY

Roche Holdings Ltd AG (QX) (RHHBY) Aktie

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Current Price

51,74

( -0,23% )

Gebot

51,39

Fragen

52,07

Volumen

1.402.427

50,96 Tagesbereich 52,06

37,51 52-Wochen-Bereich 60,85

Marktkapitalisierung

41,165B

Handelsende

51,86

Handelsbeginn

51,00

Letzte Trade

141

51.005

(average)

Letzter Handelszeitpunkt

Finanzvolumen

US$ 72.570.668

VWAP

51,7465

Durchschnittliches Volumen (3 Mio.)

US$ 1.016.346

Ausgegebene Aktien

795.617.637

Dividendenrendite (LTM)

9,8 (3,11%)

Kurs-Gewinn-Verhältnis

19,94

Gewinn pro Aktie (EPS)

16,04

Erlöse (LTM)

63,36B

Nettogewinn (LTM)

12,88B

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases... Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland. Mehr anzeigen

Sektor

Healthcare

Branche

Pharmaceuticals

Website

www.roche.com

Hauptsitz

Basel, Switzerland

Gegründet

1896

Roche Holdings Ltd AG (QX) is listed in the Healthcare sector of the OTC Markets with ticker RHHBY. The last closing price for Roche (QX) was US$51,86. Over the last year, Roche (QX) shares have traded in a share price range of US$ 37,51 to US$ 60,85.

Roche (QX) currently has 795.617.637 shares in issue. The market capitalisation of Roche (QX) is US$41,17 billion. Roche (QX) has a price to earnings ratio (PE ratio) of 19.94.

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple SclerosisBioMedWire Editorial Coverage: Multiple...

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis (“MS”...

FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma

– Filing acceptance based on data from the Phase III SUNMO study where subcutaneous Lunsumio VELO plus Polivy demonstrated a 59% reduction in risk...

FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer

Filing acceptance is based on the Phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or death risk by 50...

Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies

Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and...

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Strategic collaboration combines Nurix’s leadership in targeted protein degradation with Roche’s portfolio of...

Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection

Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for...

Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection

Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for...

FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting

Filing acceptance, under priority review, based on Phase III data showing giredestrant reduced the risk of invasive disease recurrence or death...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	2.66	5.41972290139	49.08	52.06	48.94	1839170	50.36156392	DR
4	-1.1	-2.08175624527	52.84	52.97	48.1	1715033	50.53568397	DR
12	2.23	4.50414057766	49.51	53.54	48.1	2140856	51.04109481	DR
26	-0.8	-1.52264940997	52.54	60.85	47.05	2422525	53.04145773	DR
52	10.9	26.6895200784	40.84	60.85	37.51	2094843	49.33888646	DR
156	13.22	34.3198338525	38.52	60.85	29.2	2098713	40.78527721	DR
260	4.53	9.59542469816	47.21	60.85	27.95	1886667	41.4106281	DR

RHHBY - Frequently Asked Questions (FAQ)

What is the current Roche Holdings Ltd AG (QX) share price?

The current share price of Roche Holdings Ltd AG (QX) is US$ 51,74

How many Roche Holdings Ltd AG (QX) shares are in issue?

Roche Holdings Ltd AG (QX) has 795.617.637 shares in issue

What is the market cap of Roche Holdings Ltd AG (QX)?

The market capitalisation of Roche Holdings Ltd AG (QX) is USD 41,17B

What is the 1 year trading range for Roche Holdings Ltd AG (QX) share price?

Roche Holdings Ltd AG (QX) has traded in the range of US$ 37,51 to US$ 60,85 during the past year

What is the PE ratio of Roche Holdings Ltd AG (QX)?

The price to earnings ratio of Roche Holdings Ltd AG (QX) is 19,94

What is the cash to sales ratio of Roche Holdings Ltd AG (QX)?

The cash to sales ratio of Roche Holdings Ltd AG (QX) is 4,02

What is the registered address of Roche Holdings Ltd AG (QX)?

The registered address for Roche Holdings Ltd AG (QX) is Grenzacherstrasse 124, Basel, Basel-Stadt, 4070

What is the Roche Holdings Ltd AG (QX) website address?

The website address for Roche Holdings Ltd AG (QX) is www.roche.com

Which industry sector does Roche Holdings Ltd AG (QX) operate in?

Roche Holdings Ltd AG (QX) operates in the Pharmaceuticals sector

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Roche Holdings Ltd AG (QX) (RHHBY)

Roche Holdings Ltd AG (QX) (RHHBY) Aktie

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Über Roche Holdings Ltd AG (QX)

RHHBY Neueste Nachrichten

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma

FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer

Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection

Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection

FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma

FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer

Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection

Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection

FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting

Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions

Genentech Highlights New Breast Cancer and Precision Oncology Data Ahead of ASCO 2026 (RHHBY)

Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer

RHHBY - Frequently Asked Questions (FAQ)

RHHBY Trades

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Registrieren Sie sich GRATIS und erhalten Sie:

Werbung entfernen